Welcome to Dispensed, Business Insider’s weekly healthcare newsletter. Andrew Dunn checking in for this week’s round-up.
Are you new to the newsletter? You can sign up here.
Some highlights of the week: Pricing levels on coronavirus vaccines are coming into view, digital health saw its largest-ever deal (Telavongo!), and a buzzy primary-care startup went public.
As a reminder:
We now have a daily version of Dispensed! Subscribe here to get updates from the healthcare team in your inbox every day, not just Friday.
New to Business Insider’s paywall? Use my link here to get 20% off your subscription.
Teladoc is acquiring Livongo in the biggest deal that digital health has ever seen. Here are the 3 key takeaways from Wall Street’s top analysts, from shock at the price tag to optimism for healthcare’s digital future.
Digital health companies have certainly not let a good crisis go to waste. And the coronavirus has turned into a doozy of a crisis.
Teladoc Health and Livongo Health have both seen surges in demand for their services — and stocks — stemming from the pandemic. Now, Teladoc is buying Livongo in the largest-ever deal for the growing digital health industry.
It’s an open debate as to whether Teladoc overpaid or made a savvy deal to create a force in digital health. As BI’s Blake Dodge reports, analysts think this deal “could prove to be more significant than the oft-touted ambitions of tech giants like Amazon.”
But the interests of tech giants still hover over the entire space. Amazon, Google, and Microsoft have seized opportunities presented by the pandemic to move ahead in entering the $3.6 trillion US healthcare industry, Blake writes. As health systems go to the cloud and medical care moves online, the tech giants are offering a combination of tools and scale to play a role.
You can read the full story here>>
Blake also recently talked with Chris Sakalosky, Google’s managing director of healthcare and life sciences, about these trends, particularly how Google is betting on telehealth services like Google Meet and bots.
The man who helps hospitals and clinics move to Google’s cloud shares how the coronavirus pandemic is shaping its healthcare push
Moderna has already struck deals to sell small quantities of its coronavirus vaccine for almost twice as much as rival shots. Here’s how the upstart biotech is thinking about pricing its vaccine.
A pricing controversy is brewing in the coronavirus vaccine race.
Some pharma giants have pledged not to profit off their vaccines during the pandemic, with the US government effectively paying $4 per dose for AstraZeneca’s vaccine and $10 per shot for Johnson & Johnson’s.
Moderna and Pfizer, on the other hand, have been clear they want to make a business out of their vaccines, while still vowing to behave responsibly. Pfizer reached a deal with the US at $19.50 per dose, leaving Moderna as the biggest mystery.
The Massachusetts biotech gave a clue on its earnings call this week, disclosing the …read more
Source:: Business Insider